Dr Agarwals Health Care Ltd
Fri 22/05/2026,15:50:55 | NSE : AGARWALEYE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 487.90
Previous Close
₹ 481.10
Volume
247509
Mkt Cap ( Rs. Cr)
₹15194.58
High
₹ 496.45
Low
₹ 475.95
52 Week High
₹ 568.00
52 Week Low
₹ 327.00
Book Value Per Share
₹ 62.29
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on Dr Agarwals Health Care Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
479.35
750
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
750
Option Chain
Analyzes market sentiment, predicts Dr Agarwals Health Care Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Dr. Agarwals Health - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Dr. Agarwals Health - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Dr. Agarwals Health Q4 net profit down 60.02% at Rs 10.60 cr
-
Dr. Agarwals Health - ESOP/ESOS/ESPS
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Dr. Agarwals Health - Investor Presentation
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Dr. Agarwals Health - Consolidated And Standalone Audited Financial Results Of The Company For The Quarter And Year Ended Mar
-
Dr. Agarwals Health - Outcome of Board Meeting
-
Dr. Agarwals Health - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
-
Dr. Agarwals Health - Monitoring Agency Report
-
Dr. Agarwals Health - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
-
Dr. Agarwals Health - Analysts/Institutional Investor Meet/Con. Call Updates
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Dr. Agarwals Health - Board Meeting Intimation for Consideration And Approval Of The Audited Financial Results (Standalone An
-
Dr. Agarwals Health - General Updates
-
Dr. Agarwals Health - Receipt Of Order Passed By The Hon'Ble NCLT, In Relation To The Scheme Of Amalgamation Between Dr. Agar
-
Dr. Agarwals Health has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Dr. Agarwals Health - ESOP/ESOS/ESPS
-
Dr. Agarwals Health - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
Dr. Agarwals Health - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Dr. Agarwals Health - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Dr. Agarwals Health - General Updates
-
Dr. Agarwals Health - Update On Announcement Under Regulation 30 (LODR) Dated February 03, 2026
-
Dr. Agarwals Health - Trading Window
-
Dr. Agarwals Health - Disclosure under SEBI Takeover Regulations
-
Dr. Agarwals Health - Disclosure under SEBI Takeover Regulations
-
Dr. Agarwals Health - Disclosure under SEBI Takeover Regulations
-
Dr. Agarwals Health - Disclosure under SEBI Takeover Regulations
Key fundamentals
Evaluate the intrinsic value of Dr Agarwals Health Care Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 2062.52 | 2078.86 | 1559.19 | 868.81 | 450.768 |
| Liabilities | 2062.52 | 2078.86 | 1559.19 | 868.81 | 450.768 |
| Equity | 31.68 | 31.59 | 9.33 | 7.93 | 6.86 |
| Gross Profit | 307.57 | 245.1 | 221.1 | 159.28 | 84.5478 |
| Net Profit | 39.45 | 21.93 | 23.83 | 31.59 | -1.4741 |
| Cash From Operating Activities | 320.72 | 208 | 221.58 | 152.69 | 78.2919 |
| NPM(%) | 3.05 | 2.1 | 2.85 | 5.28 | -0.4 |
| Revenue | 1293.39 | 1043.89 | 835.06 | 597.64 | 361.5898 |
| Expenses | 985.82 | 798.79 | 613.96 | 438.36 | 277.042 |
| ROE(%) | 1.99 | 1.11 | 1.2 | 1.59 | -0.07 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Dr Agarwals Health Care Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.80 | -0.07 | 0.00 | 273.55 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 109.19 | 1.26 | 352.23 | 996.77 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.00 | 0.14 | 0.00 | 6253.05 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 771.80 | 4.77 | 0.00 | 939.97 | -363.15 | 0.00 |
Company Info
Our Company was incorporated as `Dr. Agarwal's Health Care Limited' at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.Major Events and Milestones:2010- Incorporation of our Company.- Entry into the Telangana (formerly a part of Andhra Pradesh) and Karnataka markets by entering into lease agreements for setting up eye clinics.2011- Investment by EILSF SPV 3 in our Company.2012- Entry into the Africa market by entering into an agreement with Dr, Amelia Buque to jointly promote eye hospitals and other health care related services in Mozambique.2017- Entry into the Maharashtra market through the acquisition of hospital facilities in Maharashtra.2019- Investment by Claymore Investments (Mauritius) Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited and Value Growth Investment Holdings Pte. Ltd in our Company through subscription of equity shares.- Subscription of NCDs by British International Investment (formerly known as CDC Group PLC) in our Company.2021- Our Company launched its 100th eye care facility.2022- Investment by TPG Capital's Hyperion Investments Pte. Ltd. and Arvon Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited in our Company through subscription of equity shares.- Entry into the Jammu market through the acquisition of Dr. Sood eye care practices from Dr. Rohan and Raj Deep Sood.- Strengthened presence in the Gujarat market through acquisition of the eye care business from Prizma Eyecare LLP, Dr. Sanjay Vallabhai Savani and Dr. Ashish P. Gusani2023- Strengthened presence in the Punjab market through the acquisition of Punjab Eye Hospital from Dr. Gurpal Singh2024- Entry in the Uttar Pradesh market through the acquisition of an eye care business in Varanasi.- Expanded our presence in Punjab market by acquisition of Dr Thind Eye Care Private Limited.
Our Company was incorporated as `Dr. Agarwal's Health Care Limited' at Chennai, Tamil Nadu as a public limited company under the Companies Act, 1956, pursuant to the certificate of incorporation dated April 19, 2010, issued by the RoC and commenced operations pursuant to the certificate for commencement of business dated May 29, 2010, issued by the RoC.Major Events and Milestones:2010- Incorporation of our Company.- Entry into the Telangana (formerly a part of Andhra Pradesh) and Karnataka markets by entering into lease agreements for setting up eye clinics.2011- Investment by EILSF SPV 3 in our Company.2012- Entry into the Africa market by entering into an agreement with Dr, Amelia Buque to jointly promote eye hospitals and other health care related services in Mozambique.2017- Entry into the Maharashtra market through the acquisition of hospital facilities in Maharashtra.2019- Investment by Claymore Investments (Mauritius) Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited and Value Growth Investment Holdings Pte. Ltd in our Company through subscription of equity shares.- Subscription of NCDs by British International Investment (formerly known as CDC Group PLC) in our Company.2021- Our Company launched its 100th eye care facility.2022- Investment by TPG Capital's Hyperion Investments Pte. Ltd. and Arvon Investments Pte. Ltd., an indirect wholly owned subsidiary of Temasek Holdings (Private) Limited in our Company through subscription of equity shares.- Entry into the Jammu market through the acquisition of Dr. Sood eye care practices from Dr. Rohan and Raj Deep Sood.- Strengthened presence in the Gujarat market through acquisition of the eye care business from Prizma Eyecare LLP, Dr. Sanjay Vallabhai Savani and Dr. Ashish P. Gusani2023- Strengthened presence in the Punjab market through the acquisition of Punjab Eye Hospital from Dr. Gurpal Singh2024- Entry in the Uttar Pradesh market through the acquisition of an eye care business in Varanasi.- Expanded our presence in Punjab market by acquisition of Dr Thind Eye Care Private Limited.
Read More
Parent Organisation
Dr. Agarwals Health Care Ltd.
Founded
19/04/2010
Managing Director
Dr.Adil Agarwal
NSE Symbol
AGARWALEYEEQ
FAQ
The current price of Dr Agarwals Health Care Ltd is ₹ 479.35.
The 52-week high for Dr Agarwals Health Care Ltd is ₹ 496.45 and the 52-week low is ₹ 475.95.
The market capitalization of Dr Agarwals Health Care Ltd is currently ₹ 15194.58. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Dr Agarwals Health Care Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Dr Agarwals Health Care Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Dr Agarwals Health Care Ltd shares.
The CEO of Dr Agarwals Health Care Ltd is Dr.Adil Agarwal, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
